Display options
Cite
Bashutski JD, Wang HL. Biologic Agents to Promote Periodontal Regeneration and Bone Augmentation. Clin Adv Periodontics. 2011;1(2):80-87doi: 10.1902/cap.2011.110044.
Bashutski, J. D., & Wang, H. L. (2011). Biologic Agents to Promote Periodontal Regeneration and Bone Augmentation. Clinical advances in periodontics, 1(2), 80-87. https://doi.org/10.1902/cap.2011.110044
Bashutski, Jill D, and Wang, Hom-Lay. "Biologic Agents to Promote Periodontal Regeneration and Bone Augmentation." Clinical advances in periodontics vol. 1,2 (2011): 80-87. doi: https://doi.org/10.1902/cap.2011.110044
Bashutski JD, Wang HL. Biologic Agents to Promote Periodontal Regeneration and Bone Augmentation. Clin Adv Periodontics. 2011 Aug;1(2):80-87. doi: 10.1902/cap.2011.110044. PMID: 32698555.
Copy Download .nbib Format: NLM
Share it on

Clin Adv Periodontics. 2011 Aug;1(2):80-87. doi: 10.1902/cap.2011.110044.

Biologic Agents to Promote Periodontal Regeneration and Bone Augmentation.

Clinical advances in periodontics

Jill D Bashutski, Hom-Lay Wang

Affiliations

  1. Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI.

PMID: 32698555 DOI: 10.1902/cap.2011.110044

Abstract

Periodontal regeneration is preferred over tissue repair and is accomplished through the exclusion of epithelial tissues, which allows cementum, bone, and connective tissue to repopulate the wound. Recently, biologic materials have emerged as adjuncts to aid in regeneration by augmenting the events of wound healing in the area. A review of biologic agents was conducted using the following MeSH terms: guided tissue regeneration, intercellular signaling peptides and proteins, and biologic factors. Enamel matrix derivative (EMD), platelet-derived growth factor (PDGF), platelet-rich plasma, bone morphogenetic proteins (BMPs), fibroblast growth factor (FGF), and parathyroid hormone (PTH) have all shown promise in promoting hard- or soft-tissue regeneration. No biologic agent is ideal for all clinical situations so the clinician must evaluate each situation to identify the best indication for its usage. Currently, EMD and PDGF have Food and Drug Administration approval for periodontal regeneration, whereas BMP-2 is approved for bone augmentation. FGF and PTH do not have Food and Drug Administration approval for periodontal applications and so their clinical usage is not indicated.

© 2011 American Academy of Periodontology.

Keywords: Guided tissue regeneration, periodontal; platelet‐derived growth factor

References

  1. Melcher AH. On the repair potential of periodontal tissues. J Periodontol 1976; 47: 256–260. - PubMed
  2. Mellonig JT, Nevins M, Sanchez R. Evaluation of a bioabsorbable physical barrier for guided bone regeneration. Part II. Material and a bone replacement graft. Int J Periodontics Restorative Dent 1998; 18: 129–137. - PubMed
  3. Schwartz Z, Mellonig JT, Carnes DL Jr., et al. Ability of commercial demineralized freeze‐dried bone allograft to induce new bone formation. J Periodontol 1996; 67: 918–926. - PubMed
  4. Gouldin AG, Fayad S, Mellonig JT. Evaluation of guided tissue regeneration in interproximal defects. (II). Membrane and bone versus membrane alone. J Clin Periodontol 1996; 23: 485–491. - PubMed
  5. Laurell L, Gottlow J, Zybutz M, Persson R. Treatment of intrabony defects by different surgical procedures. A literature review. J Periodontol 1998; 69: 303–313. - PubMed
  6. Eickholz P, Krigar DM, Kim TS, Reitmeir P, Rawlinson A. Stability of clinical and radiographic results after guided tissue regeneration in infrabony defects. J Periodontol 2007; 78: 37–46. - PubMed
  7. Murphy KG, Gunsolley JC. Guided tissue regeneration for the treatment of periodontal intrabony and furcation defects. A systematic review. Ann Periodontol 2003; 8: 266–302. - PubMed
  8. Giannobile WV, Somerman MJ. Growth and amelogenin‐like factors in periodontal wound healing. A systematic review. Ann Periodontol 2003; 8: 193–204. - PubMed
  9. Nevins M, Giannobile WV, McGuire MK, et al. Platelet‐derived growth factor stimulates bone fill and rate of attachment level gain: Results of a large multicenter randomized controlled trial. J Periodontol 2005; 76: 2205–2215. - PubMed
  10. Jung RE, Glauser R, Schärer P, Hämmerle CH, Sailer HF, Weber FE. Effect of rhBMP‐2 on guided bone regeneration in humans. Clin Oral Implants Res 2003; 14: 556–568. - PubMed
  11. Heijl L, Heden G, Svärdström G, Ostgren A. Enamel matrix derivative (EMDOGAIN) in the treatment of intrabony periodontal defects. J Clin Periodontol 1997; 24: 705–714. - PubMed
  12. Bashutski JD, Eber RM, Kinney JS, et al. Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 2010; 363: 2396–2405. - PubMed
  13. Lindskog S, Hammarström L. Formation of intermediate cementum. III. 3H‐tryptophan and 3H‐proline uptake into the epithelial root sheath of Hertwig in vitro. J Craniofac Genet Dev Biol 1982; 2: 171–177. - PubMed
  14. Bosshardt DD. Biological mediators and periodontal regeneration: A review of enamel matrix proteins at the cellular and molecular levels. J Clin Periodontol 2008; 35 (Suppl. 8): 87–105. - PubMed
  15. Casarin RC, Ribeiro Edel P, Nociti FH Jr., et al. Enamel matrix derivative proteins for the treatment of proximal class II furcation involvements: A prospective 24‐month randomized clinical trial. J Clin Periodontol 2010; 37: 1100–1109. - PubMed
  16. Hoffmann T, Richter S, Meyle J, et al. A randomized clinical multicentre trial comparing enamel matrix derivative and membrane treatment of buccal class II furcation involvement in mandibular molars. Part III. Patient factors and treatment outcome. J Clin Periodontol 2006; 33: 575–583. - PubMed
  17. Dereka XE, Markopoulou CE, Vrotsos IA. Role of growth factors on periodontal repair. Growth Factors 2006; 24: 260–267. - PubMed
  18. Sorensen RG, Wikesjö UM, Kinoshita A, Wozney JM. Periodontal repair in dogs: Evaluation of a bioresorbable calcium phosphate cement (Ceredex) as a carrier for rhBMP‐2. J Clin Periodontol 2004; 31: 796–804. - PubMed
  19. Takahashi D, Odajima T, Morita M, Kawanami M, Kato H. Formation and resolution of ankylosis under application of recombinant human bone morphogenetic protein‐2 (rhBMP‐2) to class III furcation defects in cats. J Periodontal Res 2005; 40: 299–305. - PubMed
  20. Dohan DM, Choukroun J, Diss A, et al. Platelet‐rich fibrin (PRF): A second‐generation platelet concentrate. Part I. Technological concepts and evolution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 101: e37–e44. - PubMed
  21. Cochran DL, Wozney JM. Biological mediators for periodontal regeneration. Periodontol 2000 1999; 19: 40–58. - PubMed
  22. Hurley MM, Okada Y, Xiao L, et al. Impaired bone anabolic response to parathyroid hormone in Fgf2−/− and Fgf2+/− mice. Biochem Biophys Res Commun 2006; 341: 989–994. - PubMed
  23. Oi Y, Ota M, Yamamoto S, Shibukawa Y, Yamada S. Beta‐tricalcium phosphate and basic fibroblast growth factor combination enhances periodontal regeneration in intrabony defects in dogs. Dent Mater J 2009; 28: 162–169. - PubMed
  24. Sato Y, Kikuchi M, Ohata N, Tamura M, Kuboki Y. Enhanced cementum formation in experimentally induced cementum defects of the root surface with the application of recombinant basic fibroblast growth factor in collagen gel in vivo. J Periodontol 2004; 75: 243–248. - PubMed
  25. Takayama S, Murakami S, Shimabukuro Y, Kitamura M, Okada H. Periodontal regeneration by FGF‐2 (bFGF) in primate models. J Dent Res 2001; 80: 2075–2079. - PubMed
  26. Kitamura M, Nakashima K, Kowashi Y, et al. Periodontal tissue regeneration using fibroblast growth factor‐2: Randomized controlled phase II clinical trial. PLoS One 2008; 3: e2611. - PubMed
  27. Barros SP, Silva MA, Somerman MJ, Nociti FH Jr. Parathyroid hormone protects against periodontitis‐associated bone loss. J Dent Res 2003; 82: 791–795. - PubMed
  28. Jung RE, Cochran DL, Domken O, et al. The effect of matrix bound parathyroid hormone on bone regeneration. Clin Oral Implants Res 2007; 18: 319–325. - PubMed
  29. Jung RE, Hämmerle CH, Kokovic V, Weber FE. Bone regeneration using a synthetic matrix containing a parathyroid hormone peptide combined with a grafting material. Int J Oral Maxillofac Implants 2007; 22: 258–266. - PubMed
  30. Miller SC, Hunziker J, Mecham M, Wronski TJ. Intermittent parathyroid hormone administration stimulates bone formation in the mandibles of aged ovariectomized rats. J Dent Res 1997; 76: 1471–1476. - PubMed
  31. Crea A, Dassatti L, Hoffmann O, Zafiropoulos GG, Deli G. Treatment of intrabony defects using guided tissue regeneration or enamel matrix derivative: A 3‐year prospective randomized clinical study. J Periodontol 2008; 79: 2281–2289. - PubMed
  32. Francetti L, Trombelli L, Lombardo G, et al. Evaluation of efficacy of enamel matrix derivative in the treatment of intrabony defects: A 24‐month multicenter study. Int J Periodontics Restorative Dent 2005; 25: 461–473. - PubMed
  33. Jepsen S, Topoll H, Rengers H, et al. Clinical outcomes after treatment of intra‐bony defects with an EMD/synthetic bone graft or EMD alone: A multicentre randomized‐controlled clinical trial. J Clin Periodontol 2008; 35: 420–428. - PubMed
  34. Sculean A, Kiss A, Miliauskaite A, Schwarz F, Arweiler NB, Hannig M. Ten‐year results following treatment of intra‐bony defects with enamel matrix proteins and guided tissue regeneration. J Clin Periodontol 2008; 35: 817–824. - PubMed
  35. Grusovin MG, Esposito M. The efficacy of enamel matrix derivative (Emdogain) for the treatment of deep infrabony periodontal defects: A placebo‐controlled randomised clinical trial. Eur J Oral Implantology 2009; 2: 43–54. - PubMed
  36. Howell TH, Fiorellini JP, Paquette DW, Offenbacher S, Giannobile WV, Lynch SE. A phase I/II clinical trial to evaluate a combination of recombinant human platelet‐derived growth factor‐BB and recombinant human insulin‐like growth factor‐I in patients with periodontal disease. J Periodontol 1997; 68: 1186–1193. - PubMed
  37. Lynch SE, de Castilla GR, Williams RC, et al. The effects of short‐term application of a combination of platelet‐derived and insulin‐like growth factors on periodontal wound healing. J Periodontol 1991; 62: 458–467. - PubMed
  38. Piemontese M, Aspriello SD, Rubini C, Ferrante L, Procaccini M. Treatment of periodontal intrabony defects with demineralized freeze‐dried bone allograft in combination with platelet‐rich plasma: A comparative clinical trial. J Periodontol 2008; 79: 802–810. - PubMed
  39. Sammartino G, Tia M, Gentile E, Marenzi G, Claudio PP. Platelet‐rich plasma and resorbable membrane for prevention of periodontal defects after deeply impacted lower third molar extraction. J Oral Maxillofac Surg 2009; 67: 2369–2373. - PubMed
  40. Graziani F, Ivanovski S, Cei S, Ducci F, Tonetti M, Gabriele M. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin Oral Implants Res 2006; 17: 212–219. - PubMed
  41. Jung RE, Windisch SI, Eggenschwiler AM, Thoma DS, Weber FE, Hämmerle CH. A randomized‐controlled clinical trial evaluating clinical and radiological outcomes after 3 and 5 years of dental implants placed in bone regenerated by means of GBR techniques with or without the addition of BMP‐2. Clin Oral Implants Res 2009; 20: 660–666. - PubMed
  42. Triplett RG, Nevins M, Marx RE, et al. Pivotal, randomized, parallel evaluation of recombinant human bone morphogenetic protein‐2/absorbable collagen sponge and autogenous bone graft for maxillary sinus floor augmentation. J Oral Maxillofac Surg 2009; 67: 1947–1960. - PubMed
  43. Boyne PJ, Lilly LC, Marx RE, et al. De novo bone induction by recombinant human bone morphogenetic protein‐2 (rhBMP‐2) in maxillary sinus floor augmentation. J Oral Maxillofac Surg 2005; 63: 1693–1707. - PubMed
  44. Trombelli L, Farina R. Clinical outcomes with bioactive agents alone or in combination with grafting or guided tissue regeneration. J Clin Periodontol 2008; 35 (Suppl. 8): 117–135. - PubMed
  45. Sculean A, Pietruska M, Arweiler NB, Auschill TM, Nemcovsky C. Four‐year results of a prospective‐controlled clinical study evaluating healing of intra‐bony defects following treatment with an enamel matrix protein derivative alone or combined with a bioactive glass. J Clin Periodontol 2007; 34: 507–513. - PubMed
  46. Wikesjö UM, Qahash M, Thomson RC, et al. rhBMP‐2 significantly enhances guided bone regeneration. Clin Oral Implants Res 2004; 15: 194–204. - PubMed
  47. Saito E, Saito A, Kawanami M. Favorable healing following space creation in rhBMP‐2‐induced periodontal regeneration of horizontal circumferential defects in dogs with experimental periodontitis. J Periodontol 2003; 74: 1808–1815. - PubMed
  48. Simon BI, Zatcoff AL, Kong JJ, O'Connell SM. Clinical and histological comparison of extraction socket healing following the use of autologous platelet‐rich fibrin matrix (PRFM) to ridge preservation procedures employing demineralized freeze dried bone allograft material and membrane. Open Dent J 2009; 3: 92–99. - PubMed
  49. Mazor Z, Horowitz RA, Del Corso M, Prasad HS, Rohrer MD, Dohan Ehrenfest DM. Sinus floor augmentation with simultaneous implant placement using Choukroun's platelet‐rich fibrin as the sole grafting material: A radiologic and histologic study at 6 months. J Periodontol 2009; 80: 2056–2064. - PubMed
  50. Camargo PM, Lekovic V, Weinlaender M, Divnic‐Resnik T, Pavlovic M, Kenney EB. A surgical reentry study on the influence of platelet‐rich plasma in enhancing the regenerative effects of bovine porous bone mineral and guided tissue regeneration in the treatment of intrabony defects in humans. J Periodontol 2009; 80: 915–923. - PubMed
  51. Döri F, Nikolidakis D, Húszár T, Arweiler NB, Gera I, Sculean A. Effect of platelet‐rich plasma on the healing of intrabony defects treated with an enamel matrix protein derivative and a natural bone mineral. J Clin Periodontol 2008; 35: 44–50. - PubMed
  52. You TM, Choi BH, Zhu SJ, et al. Platelet‐enriched fibrin glue and platelet‐rich plasma in the repair of bone defects adjacent to titanium dental implants. Int J Oral Maxillofac Implants 2007; 22: 417–422. - PubMed
  53. Hosokawa R, Kikuzaki K, Kimoto T, et al. Controlled local application of basic fibroblast growth factor (FGF‐2) accelerates the healing of GBR. An experimental study in beagle dogs. Clin Oral Implants Res 2000; 11: 345–353. - PubMed

Publication Types

Grant support